Improved labelling of DTPA- and DOTA-conjugated peptides and antibodies with ¹¹¹In in HEPES and MES buffer

Background

In single photon emission computed tomography [SPECT], high specific activity of ¹¹¹In-labelled tracers will allow administration of low amounts of tracer to prevent receptor saturation and/or side effects. To increase the specific activity, we studied the effect of the buffer used during the labelling procedure: NaAc, NH₄Ac, HEPES and MES buffer. The effect of the ageing of the ¹¹¹InCl₃ stock and cadmium contamination, the decay product of ¹¹¹In, was also examined in these buffers.

Methods

Escalating amounts of ¹¹¹InCl₃ were added to 1 μg of the diethylene triamine pentaacetic acid [DTPA]- and 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid [DOTA]-conjugated compounds (exendin-3, octreotide and anti-carbonic anhydrase IX [CAIX] antibody). Five volumes of 2-(N-morpholino)ethanesulfonic acid [MES], 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid [HEPES], NH₄Ac or NaAc (0.1 M, pH 5.5) were added. After 20 min at 20°C (DTPA-conjugated compounds), at 95°C (DOTA-exendin-3 and DOTA-octreotide) or at 45°C (DOTA-anti-CAIX antibody), the labelling efficiency was determined by instant thin layer chromatography. The effect of the ageing of the ¹¹¹InCl₃ stock on the labelling efficiency of DTPA-exendin-3 as well as the effect of increasing concentrations of Cd²⁺ (the decay product of ¹¹¹In) were also examined.

Results

Specific activities obtained for DTPA-octreotide and DOTA-anti-CAIX antibody were five times higher in MES and HEPES buffer. Radiolabelling of DTPA-exendin-3, DOTA-exendin-3 and DTPA-anti-CAIX antibody in MES and HEPES buffer resulted in twofold higher specific activities than that in NaAc and NH₄Ac. Labelling of DTPA-exendin-3 decreased with 66% and 73% for NaAc and NH₄Ac, respectively, at day 11 after the production date of ¹¹¹InCl₃, while for MES and HEPES, the maximal decrease in the specific activity was 10% and 4% at day 11, respectively. The presence of 1 pM Cd²⁺ in the labelling mixture of DTPA-exendin-3 in NaAc and NH₄Ac markedly reduced the labelling efficiency, whereas Cd²⁺ concentrations up to 0.1 nM did not affect the labelling efficiency in MES and HEPES buffer.

Conclusions

We showed improved labelling of DTPA- and DOTA-conjugated compounds with ¹¹¹In in HEPES and MES buffer. The enhanced labelling efficiency appears to be due to the reduced competitive chelation of cadmium. The enhanced labelling efficiency will allow more sensitive imaging of the biomarkers with SPECT.

Radiolabelled peptides and antibodies are used for molecular imaging and radionuclide therapy of tumours. The most successful example of peptide receptor imaging is the somatostatin analogue octreotide, which targets the somatostatin receptor subtype 2, overexpressed on neuroendocrine tumours. Tracers labelled with a radiometal via a chelator have the advantage that they can be labelled with high efficiency (> 95%) without the need for post-labelling purification and that the metabolites are trapped in the lysosomes of the cell, leading to higher accumulation in the target cell. This phenomenon is referred to as 'metabolic trapping' [1–5]. Ideally, low peptide or protein doses are administered because high doses may lead to saturation of the receptor, resulting in reduced accumulation of the radiotracer in the target tissue [6]. In addition, higher doses may cause toxic side effects, especially when agonists are used. In order to administer activity doses sufficient for imaging (single photon emission computed tomography or planar scintigraphy), tracers with a high specific activity [SA] are required. There is a need to further increase the SA to improve image quality, especially in the preclinical setting. In general, the tracer doses administered in rodent models must be kept low while at the same time administering relatively high activity doses (> 10 MBq/animal). ¹¹¹In is a widely used radionuclide for the labelling of peptides and proteins used for imaging purposes. To enable labelling with a radiometal, such as ¹¹¹In, the targeting molecule has to be conjugated with a chelator. The most commonly used chelators are diethylene triamine pentaacetic acid [DTPA] and 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid [DOTA]. Labelling of DTPA- and DOTA-conjugated compounds is a one-step reaction in which the conjugated compound is incubated with ¹¹¹InCl₃ in a slightly acidic buffer, keeping the pH between 4 and 5.5. Acetate buffers are commonly used as a buffer for ¹¹¹In-labelling of DTPA- and DOTA-conjugated compounds. Acetate buffers readily form coordination complexes with metals. It is assumed that coordinating buffers are needed for efficient chelation of radiometals [7]. However, for ⁶⁸Ga-labelling of DOTA-conjugated compounds, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid [HEPES] is successfully used as a buffer. Although developed for biological purposes by Good et al., HEPES has beneficial characteristics in chemistry involving metal ions as a non-coordinating buffer [8]. 2-(N-morpholino)ethanesulfonic acid [MES] was also described as a 'good buffer' [8] and has similar characteristics. Although HEPES and MES were described as non-coordinating buffers, recent reports showed that HEPES forms weak complexes with Cu(II) and Pb(II), but not with Zn(II) or Cd(II) [9, 10]. Therefore, the term 'weakly coordinating' buffers seems to be more appropriate.

The fact that HEPES is successfully used for labelling of compounds with ⁶⁸Ga prompted us to examine the effect of the weakly coordinating buffers, HEPES and MES, on the ¹¹¹In-labelling and compared this with the radiolabelling in routinely used acetate buffer (sodium acetate and ammonium acetate). For comparison of the radiolabelling in these buffers, two peptides, exendin-3 and octreotide, and the chimeric monoclonal antibody [mAb] targeting carbonic anhydrase IX [CAIX], each conjugated with DTPA or DOTA, were used.

Peptides and antibodies and conjugation with DTPA or DOTA

DTPA-Tyr³-octreotide, DOTA-Tyr³-octreotide, [Lys⁴⁰(DTPA)]exendin-3 [DTPA-exendin-3] and [Lys⁴⁰(DOTA)]exendin-3 [DOTA-exendin-3] [11] were purchased from Peptide Specialty Laboratories GmbH (Heidelberg, Germany). The chimeric mAb anti-CAIX (cG250) was obtained from Wilex AG (Munich, Germany). The conjugation of anti-CAIX with SCN-Bz-DTPA or SCN-Bz-DOTA (Macrocyclics, Dallas, TX, USA) with a 50-fold molar excess was performed in a 0.1 M NaHCO₃ buffer, with a pH of 8.2. After 1-h incubation, the conjugation mixture was dialyzed in a dialysis cell with a molecular cut-off value of 20 kD (Slide-a-lyzer, Pierce, Rockford, IL, USA) against 0.25 M ammonium acetate (pH 5.5) with five buffer changes to remove the unconjugated SCN-Bz-DTPA and SCN-Bz-DOTA. After conjugation, the protein concentration was determined spectrophotometrically (Amersham Pharmacia Biotech, Uppsala, Sweden) at 280 nm. The substitution ratio was determined by the labelling of the conjugation mixture with ¹¹¹InCl₃ (Covidien, Petten, The Netherlands) described by Hnatowich et al. [12]. After incubation at room temperature [RT] for 20 min, quality control was performed on silica-gel instant thin layer chromatography [ITLC] strips (ITLC-SG, Biodex Medical Systems, Inc., Shirley, NY, USA) with sodium citrate, with a pH of 5.5, as the mobile phase (retention factor [R _f] ¹¹¹In-labelled anti-CAIX mAb = 0, R _f ¹¹¹In-DTPA or ¹¹¹In-DOTA = 1). The substitution ratio is represented by the percentage of activity with an R _f of 0 when the conjugation mixture is labelled.

Buffers

Sodium acetate (Merck, Darmstadt, Germany) was dissolved in distilled water (Versol, Lyon, France) to a final concentration of 0.1 M, and the pH was adjusted to 5.5 by titration with 1 M HCl (Merck, Darmstadt, Germany). Ammonium acetate buffer was prepared by mixing equal volumes of 0.2 M acetic acid (Merck, Darmstadt, Germany) and 0.2 M ammonia (Merck, Darmstadt, Germany), and the pH was adjusted to 5.5 by adding 0.2 M acetic acid or 0.2 M ammonia. MES and HEPES (Sigma-Aldrich Corporation, St. Louis, MO, USA) were dissolved in distilled water to a final concentration of 0.1 M, and the pH was adjusted to 5.5 with 1 M NaOH (Merck, Darmstadt, Germany).

¹¹¹In-labelling of peptides and antibodies

The labelling of the six compounds with ¹¹¹In was performed 9 days after ¹¹¹In production (The calibration date of ¹¹¹InCl₃ is 10 days after the production of ¹¹¹InCl₃, and the expiry date of ¹¹¹InCl₃ is 11 days after the production of ¹¹¹InCl₃). The peptides and antibodies were dissolved in metal-free water to a final concentration of 0.1 μg/μl, and 5 μl was added to a 0.1 M NaAc, NH4Ac, MES or HEPES buffer. Five volumes of buffer and one volume of ¹¹¹InCl₃ (Covidien, Petten, The Netherlands) were added. The reaction mixtures were incubated for 20 min at RT for DTPA-conjugated compounds, at 95°C for DOTA-exendin and DOTA-octreotide or at 45°C for the DOTA-conjugated anti-CAIX antibody. After incubation, Tween80 (Sigma-Aldrich Corporation, St. Louis, MO, USA) was added to a final concentration of 0.1%, and ethylenediaminetetraacetic acid [EDTA] (Sigma-Aldrich Corporation, St. Louis, MO, USA) in 0.25 M NH₄Ac, with a pH of 5.5, was added to a final concentration of 5 mM to complex unincorporated ¹¹¹In. Quality control was performed on silica-gel ITLC strips with 0.1 M EDTA in 0.1 M NH₄Ac as a mobile phase (R _f ¹¹¹In-labelled compounds = 0, R _f ¹¹¹In-EDTA = 1). The maximum SA was determined by correcting the initial SA for the radiochemical purity.

Effect of ageing of the ¹¹¹InCl₃ stock on the labelling efficiency of DTPA-exendin-3

DTPA-exendin-3 (0.5 μg) was labelled in triplicate (except for t = 14, which is in duplicate) with ¹¹¹In (75 MBq) in 0.1 M NaAc, NH₄Ac, MES and HEPES, with a pH of 5.5, as described above, from 4 days after the production date (delivery of ¹¹¹InCl₃) until 14 days after the production date of ¹¹¹InCl₃. Quality control was performed as described above.

Effect of the presence of cadmium on the labelling efficiency of DTPA-exendin-3

The effect of cadmium, the decay product of ¹¹¹In, on the radiolabelling was examined by adding increasing amounts of Cd²⁺ to the labelling mixture of DTPA-exendin-3. CdCl₂ (Sigma-Aldrich Corporation, St. Louis, MO, USA) was dissolved in 0.1 M Ultrapure HCl (J.T. Baker, Deventer, The Netherlands), and serial dilutions ranging from 10^-1 to 10^-7 M CdCl₂ in 0.02 M HCl were prepared. DTPA-exendin-3 (0.5 μg) was labelled with 1.85 MBq ¹¹¹InCl₃ (at day 9 after ¹¹¹InCl₃ production) in 0.1 M NaAc, NH₄Ac, MES and HEPES, with a pH of 5.5, as described above, and various amounts of CdCl₂ were added simultaneously with ¹¹¹InCl₃ to amounts ranging from 1 × 10^-3 to 9 × 10⁴ nmol (resulting in final concentrations of Cd²⁺ ranging from 1 pM to 8.3 μM). The amount of buffer was adjusted for the amount of CdCl₂ in 0.02 M HCl added (final pH 5.5). The experiment was performed in triplicate for all CdCl₂ concentrations and all buffers. Quality control was performed as described above.

Substitution ratio of DTPA- and DOTA-anti-CAIX

The substitution ratio of DTPA- and DOTA-anti-CAIX was 3 DTPA and 7 DOTA molecules per antibody molecule, respectively.

Effect of the buffer on the labelling efficiency of DTPA conjugates

The labelling efficiency at different specific activities of DTPA-exendin-3, DTPA-octreotide and DTPA-anti-CAIX in 0.1 M NaAc, NH₄Ac, MES and HEPES is summarized in Figure 1. The maximum specific activities of the compounds in different buffers were calculated and are shown in Figure 2 and Table 1. Labelling of DTPA-exendin-3 in NaAc buffer resulted in a maximal SA of 379 ± 16 MBq/nmol. The SA was somewhat lower when DTPA-exendin-3 was labelled in NH₄Ac, 207 ± 20 MBq/nmol. Two- to fourfold higher specific activities were observed when DTPA-exendin-3 was labelled in MES or HEPES (717 ± 29 and 837.3 ± 6 MBq/nmol, respectively). Similar results were observed for the labelling of DTPA-octreotide and DTPA-anti-CAIX (Figures 1 and 2, Table 1).

¹¹¹ In-labelling. ¹¹¹In-labelling of DTPA-exendin-3, DOTA-exendin-3, DTPA-octreotide, DOTA-octreotide, DTPA-anti-CAIX and DOTA-anti-CAIX in 0.1 M NaAc, NH₄Ac, MES and HEPES buffers.

Full size image

Maximal specific activities. Maximal specific activities (in megabecquerel per nanomole) for DTPA-exendin-3, DOTA-exendin-3, DTPA-octreotide, DOTA-octreotide, DTPA-anti-CAIX and DOTA-anti-CAIX in 0.1 M NaAc, NH₄Ac, MES and HEPES buffers.

Full size image

When DTPA-exendin-3 was labelled in MES, the SA was 42 ± 2% of the maximum theoretical SA (Figure 3). Labelling of DTPA-exendin-3 in HEPES resulted in a SA that was 49 ± 1% of the maximum theoretical SA and was higher than the SA in acetate buffers (NaAc 22 ± 1% and NH₄Ac 12 ± 1%). Similar results were obtained for the labelling of the anti-CAIX antibody, whereas the overall complexation of ¹¹¹In by DTPA-octreotide was somewhat lower for all buffers.

Percentage of the maximum theoretical SA. Percentage of the maximum theoretical SA of DTPA-exendin-3, DOTA-exendin-3, DTPA-octreotide, DOTA-octreotide, DTPA-anti-CAIX and DOTA-anti-CAIX in 0.1 M NaAc, NH₄Ac, MES and HEPES buffers.

Full size image

Effect of the buffer on the labelling efficiency of DOTA conjugates

The SA for ¹¹¹In-DOTA-exendin-3 was lower than that of ¹¹¹In-DTPA-exendin-3 (Figure 2 and Table 1). However, the same trend was observed: Labelling in MES and HEPES resulted in higher SA (56 ± 4 and 38 ± 16 MBq/nmol) compared to that in the acetate buffers (NaAc 23 ± 8 MBq/nmol and NH₄Ac 22 ± 1 MBq/nmol), with the exception that MES performed better than HEPES in these experiments (Figures 1 and 2, Table 1). Also, for DOTA-anti-CAIX, higher SA were observed in MES and HEPES buffer, 947 ± 44 and 1,018 ± 7 MBq/nmol, respectively, versus 330 ± 87 MBq/nmol for NaAc and 254 ± 2 MBq/nmol for NH₄Ac (Figures 1 and 2, Table 1). No difference in specific activities was observed for DOTA-octreotide (Figures 1 and 2, Table 1).

The complexation of ¹¹¹In by DOTA-conjugated compounds was less efficient than that by DTPA-conjugated compounds (Figure 3). The most efficient complexation of ¹¹¹In was achieved by the labelling of DOTA-anti-CAIX in HEPES buffer, 8.2 ± 0.1% of the DOTA chelates complexed an ¹¹¹In atom. Labelling in HEPES buffer resulted in similar complexation efficiency (7.6 ± 0.4%), whereas labelling in acetate buffers resulted in a three to fivefold reduction in the percentage of DOTA molecules complexed (NaAc 2.7 ± 0.7 and NH₄Ac 1.6 ± 0.4). Incorporation of ¹¹¹In was also more efficient in HEPES and MES buffer for DOTA-exendin-3, but no differences in complexation efficiency were observed when DOTA-octreotide was labelled.

Effect of ageing of the ¹¹¹InCl₃ stock on the labelling efficiency of DTPA-exendin-3

The effect of ageing of the ¹¹¹InCl₃ stock on the labelling efficiency of DTPA-exendin-3 in 0.1 M NaAc, NH₄Ac, MES and HEPES was investigated, and the results are summarized in Figures 4 and 5. Four days after the production of ¹¹¹InCl₃ (arrival of ¹¹¹InCl₃ stock), DTPA-exendin-3 could be labelled with ¹¹¹In with similar labelling efficiency, resulting in similar SA, for all buffers. In NaAc and NH₄Ac, a reduced labelling efficiency was observed as soon as 7 days after the production of ¹¹¹InCl₃, decreasing to a labelling efficiency of 34 ± 8% and 27 ± 3% for NaAc and NH₄Ac, respectively at day 11. Only a minimal decrease in labelling efficiency was observed when the labelling was performed in MES buffer: from 92.6 ± 5.2% at day 4 to 78.3 ± 3.0% at day 14. A decrease in labelling efficiency was not observed up to day 9. The time point of radiolabelling did not have any significant effect on the labelling efficiency or SA when HEPES was used for the radiolabelling. Labelling in HEPES at day 4 resulted in a labelling efficiency of 87 ± 7% with a SA 627 ± 54 MBq/nmol. A labelling efficiency of 92 ± 6% and a SA of 625 ± 54 MBq/nmol were obtained at day 14 after the production date of ¹¹¹InCl₃. These results were not significantly different from the results obtained 4 days after the production date.

Radiolabelling of DTPA-exendin-3 with ¹¹¹ In. Radiolabelling of DTPA-exendin-3 with ¹¹¹In at different time points from the production (day 0) of ¹¹¹InCl₃ for 0.1 M NaAc, NH₄Ac, MES and HEPES. Asterisk, labelling performed in duplicate; double asterisks, single labelling performed.

Full size image

Maximal SA of ¹¹¹ In-DTPA-exendin-3 at several time points after ¹¹¹ InCl ₃ production ( t = 1 day). The SA was calculated by the initial SA (712 MBq/nmol) corrected by the labelling efficiency. Asterisk, labelling performed in duplicate; double asterisks, single labelling performed.

Full size image

Effect of the presence of cadmium on the labelling efficiency of DTPA-exendin-3

In Figure 6 and Table 2 the effect of the Cd²⁺ concentration in the labelling mixture on the labelling efficiency of DTPA-exendin-3 is summarized. A decrease in labelling efficiency was observed when 1 pM CdCl₂ was added to the labelling of DTPA-exendin-3 with ¹¹¹In in NaAc and NH₄Ac, whereas up to 0.1 nM Cd²⁺ did not affect the labelling efficiency when DTPA-exendin-3 was labelled in MES or HEPES.

Effect of cadmium on labelling of ¹¹¹ In-DTPA-exendin-3 in 0.1 M NaAc, NH ₄ Ac, MES and HEPES.

Full size image

The Cd²⁺ concentration that lead to a 50% reduction in labelling efficiency was lower in NaAc (0.011 nM, 95% confidence interval 0.007 to 0.019 nM) and NH₄Ac (0.013 nM, 95% confidence interval 0.010 to 0.019 nM) than that in MES (2.5 nM, 95% confidence interval 1.5 to 4.1 nM) and HEPES (2.7, 95% confidence interval 2.2 to 3.3 nM), indicating that the labelling efficiency was not affected by Cd²⁺ contamination in MES and HEPES buffer.

High SA of ¹¹¹In-labelled peptides and antibodies is required to administer a tracer dose of peptide or protein, preventing target saturation and/or side effects, while administering high activity doses required for imaging. Acetate buffers are routinely used for the labelling of DTPA- and DOTA-conjugated compounds with ¹¹¹In. Here, we examined the effect of the buffer used during the radiolabelling: HEPES and MES, and compared this with the most commonly used acetate buffers: sodium acetate and ammonium acetate, and showed that an increased SA could be obtained when DTPA- and DOTA-conjugated compounds were labelled in MES or HEPES buffer. Moreover, the labelling efficiency was not affected by Cd²⁺ concentrations up to 0.1 nM when the labelling was performed in MES and HEPES, whereas a drastic effect was observed when the labelling was performed in acetate buffers. In line with these results, the ageing of the ¹¹¹InCl₃ stock had only a minor effect on the labelling efficiency 14 days after the production of ¹¹¹InCl₃ when compounds were labelled in MES and HEPES.

The use of MES as a buffer for radiolabelling resulted in a SA of all DTPA-conjugated compounds that was approximately two to three times higher when compared to radiolabelling in ammonium acetate and sodium acetate, respectively. When HEPES was used, an even higher SA of the DTPA-conjugated compounds was observed: four times higher than the labelling performed in ammonium acetate. The effect was less pronounced when the DOTA-conjugated compounds were labelled with ¹¹¹In. Overall, radiolabelling in HEPES and MES was more efficient than that in acetate buffers in most cases and at least as efficient as in the case of DOTA-octreotide. Labelling of DOTA-conjugated compounds resulted in 5 to 20 times lower SA than that of DTPA-conjugated compounds. Most likely, this is due to the interference of contaminating metals with DOTA chelation, which might play a role to a lesser extent when labelling DTPA-conjugated compounds.

The decay product of ¹¹¹In, ¹¹¹Cd, can also be chelated by DTPA or DOTA, and it is therefore expected that the complexation of ¹¹¹In is less efficient over time due to increasing amounts of Cd²⁺. Indeed, this phenomenon was observed when sodium acetate and ammonium acetate were used for the ¹¹¹In-labelling of DTPA-exendin. Lower labelling efficiencies were observed as early as 7 days after the production of ¹¹¹InCl₃, and threefold lower SA were obtained when the labelling was performed with ¹¹¹InCl₃ 11 days after the production date. This effect was not observed for the labelling of DTPA-exendin-3 in MES and HEPES with a maximal decrease in SA of 10% and 4% at day 11, respectively. Even the decrease in SA 14 days after the calibration date of ¹¹¹InCl₃ was not more than 18% for ¹¹¹In-labelling in MES and 5% for HEPES. These latter results could explain the differences in SA of the six compounds used in this study since the labelling of these compounds was performed with ¹¹¹In 9 days after production. Generally, ¹¹¹InCl₃ is used from 7 to 11 days after the production day, which could lead to reduced specific activities at later time points when acetate buffers are used. To overcome this problem, HEPES or MES buffer could be used for radiolabelling, with high specific activities at time points up to 14 days after ¹¹¹InCl₃ production. This could have an impact on experiment planning since experiments which require high-SA-labelled compounds are only available early after ¹¹¹In production when acetate buffers are used, whereas the time point is not relevant when MES or HEPES is used. These results suggest that increasing amounts of Cd²⁺ contamination, due to the ageing of the ¹¹¹InCl₃ stock, do not influence the labelling of DTPA-conjugated compounds when MES and HEPES are used as a buffer for radiolabelling.

The suggested effect of cadmium on the ¹¹¹In-labelling of DTPA-conjugated compounds was confirmed when increasing amounts of Cd²⁺ were added to the ¹¹¹In-labelling mixture of DTPA-exendin. In HEPES and MES buffer, a 100-fold higher amount of cadmium could be added to the labelling mixture without reducing the labelling efficiency than in acetate buffer. The decreased labelling efficiency at low concentrations of cadmium might be due to the efficient formation of coordination complexes of Cd²⁺ with acetate, allowing efficient 'transchelation' of Cd²⁺, whereas no coordination complex with HEPES or MES is formed [9], and transchelation of Cd²⁺ to DTPA or DOTA is less efficient.

It has been postulated that coordination complex formation of ¹¹¹In with acetate buffers is necessary for efficient labelling of DTPA- and DOTA-conjugated compounds [13] since it is assumed that the coordination complex formation prevents the formation of insoluble ¹¹¹In-hydroxide. This study suggests that coordination complex formation of the buffer with ¹¹¹In is less important for efficient labelling of DTPA- and DOTA-conjugated compounds since the labelling in the weakly coordinating buffers MES and HEPES was more efficient than that in acetate buffers in most cases or at least equivocal in the case of DOTA-octreotide.

Breeman et al. described the effect of contaminants on the labelling of DOTA-octreotide with ¹¹¹In, ¹⁷⁷Lu and ⁹⁰Y, and found a similar result of the effect of cadmium contamination on the radiolabelling [14]. The labelling procedures described in the latter study were performed in sodium acetate, and these findings are in line with the findings in our study, where a pronounced effect of Cd²⁺ on the labelling of DTPA-exendin-3 is observed when sodium acetate is used as buffer for radiolabelling.

The purification of ¹¹¹InCl₃ by an anion exchange method was described to improve the labelling of DTPA- and DOTA-conjugated compounds caused by the removal of contaminants, mainly Cd²⁺, present in the ¹¹¹InCl₃ solution [15]. By using HEPES or MES buffer for the labelling of the compounds, this could omit a time-consuming purification method.

We showed improved labelling of DTPA- and DOTA-conjugated peptides, proteins and antibodies with ¹¹¹In when HEPES or MES buffer was used for radiolabelling. The enhanced labelling efficiency could be due to the reduced competitive chelation of cadmium, the decay product of ¹¹¹In. When ¹¹¹In-labelling of DTPA- and DOTA-conjugated compounds is performed in MES or HEPES, ¹¹¹In-labelled compounds can be produced with high specific activities regardless from the time point after ¹¹¹In production.

Our work was supported by NIH grant 1R01 AG 030328-01 and the European Community's Seventh Framework Programme (FP7/2007-2013), project BetaImage, under grant agreement no. 222980.

Affiliations

1. Department of Nuclear Medicine, Radboud University Nijmegen Medical Centre, PO Box 9101, Nijmegen, 6500, HB, The Netherlands

   • Maarten Brom
   • , Lieke Joosten
   • , Wim JG Oyen
   • , Martin Gotthardt
   •  & Otto C Boerman

Corresponding author

Correspondence to Maarten Brom.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

MB and LJ performed the ¹¹¹In-labelling studies. MB, LJ, MG and OCB participated in the study design and coordination. MB drafted the manuscript. LJ, MG, WJGO and OCB proofread the manuscript. All authors read and approved the final manuscript.

Reprints and Permissions